ClinicalTrials.gg
CompletedNCT04090684Updated Feb 1, 2022

Ciprofloxacin/Celecoxib Combination in Patients With ALS

A Phase 1 interventional study of Fixed dose combination Ciprofloxacin/Celecoxib in ALS (Amyotrophic Lateral Sclerosis), sponsored by NeuroSense Therapeutics Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-02-01.

Sponsored by NeuroSense Therapeutics Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
246th of 307
10 · median 33
Started
2019
with 19 others
Phase 1
57 of 440
11 open now
Registered
249th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 246th largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2019, is one of 57 in phase 1, and was the 249th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital Capacity).

Read the detailed description

Patients will be prescribed a fixed dose combination of Ciprofloxacin and Celecoxib to be taken twice daily, and will be monitored for safety and tolerability. Additionally, routine progression measures will be assessed.

03

Conditions studied

  • ALS (Amyotrophic Lateral Sclerosis)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to comprehend and willing to sign an Form (ICF)
  2. Males or females between the ages of 18 and 75 years of age, inclusive
  3. Diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) less than 5 years prior to baseline
  4. Patients may be on Riluzole and/or Edaravone; 30 days of stable use is required to make safety assessments more reliable
  5. Upright Forced Vital Capacity (FVC) ≥ 50% of predicted for age, height and sex at screening
  6. Patient is able to swallow tablets/ capsules
  7. A caregiver (if one is needed)
  8. Female patients must be (≥ 1 year) OR sterilized, OR if of (i.e., females who have had their first period unless they are anatomically and physiologically incapable to become pregnant), must have a negative pregnancy test, and agree to use drugs or devices (e.g., diaphragm plus spermicide, or oral contraceptives) for the duration of the study and 10 weeks after the last treatment dose AND require male partners to use a condom during sexual intercourse

Exclusion criteria

Exclusion Criteria:

  1. A past history of adverse reaction/ to either NSAIDs, celecoxib or fluoroquinolones, ciprofloxacin
  2. Any known abnormal gastric mucosal initial gastroscopic of an erosion, ulcer or tumor or/and GI disorder
  3. Known history of impaired renal function.
  4. Known or suspected congestive heart and/or coronary heart disease, previous history of myocardial infarction, uncontrolled arterial hypertension, or rhythm abnormalities requiring permanent treatment
  5. Known history of /QTc prolongation, Torsade de pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT syndrome) and the use of concomitant medications that prolong the QT/QTc interval.
  6. Known or suspected diagnosis or family history of epilepsy
  7. Presence at screening of any medically significant cardiac, pulmonary, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety data, including, but not limited to:

    1. Mean systolic blood pressure >180 mm Hg; mean diastolic blood pressure >100 mm Hg (measurements taken after few min rest) that persist on 3 successive measurements taken at least 2 minutes apart
    2. Class II or greater congestive heart failure
    3. or asthma requiring daily use of bronchodilator medications
    4. Poorly controlled or brittle diabetes mellitus
    5. Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient's ability to understand and/or comply with study procedures and provide
  8. Female who is pregnant or breastfeeding or with intention of becoming pregnant during the course of the study
  9. Any impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study
  10. Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study
  11. Patient is participating in (or plans to participate in) any other drug trial, or plans to be exposed to any other investigational agent, device and/or procedure, from 30 days prior to Screening through study completion
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Fixed dose Ciprofloxacin and Celecoxib

    Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day

    Drug: Fixed dose combination Ciprofloxacin/Celecoxib

Interventions

  • DrugFixed dose combination Ciprofloxacin/Celecoxib

    Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day

    Also known as: PrimeC

06

What researchers measure

Primary outcomes

  1. Number of participants with one or more treatment-emergent adverse events

    Treatment emergent adverse event is any medical event associated with the drug

    Time frame: 15 months

  2. Number of patients who discontinued treatment prematurely

    Number of patients whose treatment is stopped prematurely for any reason

    Time frame: 15 months

  3. Number of patients who discontinued treatment prematurely due to adverse events

    Number of patients whose treatment is stopped prematurely specifically due to adverse events

    Time frame: 15 months

  4. Number of patients with significant abnormal laboratory values

    Time frame: 15 months

07

Study locations

1 site
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Sep 2021, 21 months.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's 21 months is close to that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2019
First posted
Sep 16, 2019
StartActual
Dec 9, 2019
Primary completionActual
Sep 27, 2021
CompletionActual
Jan 20, 2022
Last update
Feb 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04090684
Lead sponsor
NeuroSense Therapeutics Ltd.
Responsible party
Sponsor
First posted
Sep 16, 2019
Start date
Dec 9, 2019
Primary completion
Sep 27, 2021
Completion
Jan 20, 2022
Last update
Feb 1, 2022

Study contacts

Jeremy Shefner, MD, PhD
principal investigator · Barrow Neurological Institute

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion